Primary non-parasitic splenic cyst: US- and fluoroscopy-guided percutaneous management by alcohol sclerosis on six patients

J Clin Ultrasound. 2022 Nov;50(9):1360-1367. doi: 10.1002/jcu.23298. Epub 2022 Aug 30.

Abstract

Purpose: This manuscript aims to report on a retrospective analysis of six patients treated with combined US- and fluoroscopic-guided percutaneous alcohol sclerosis for primary non-parasitic splenic cysts.

Methods: In this retrospective analysis, three females and three males affected by primary non-parasitic splenic cysts were included. All except one were symptomatic. Preoperative cyst diameter was in mean 113 mm (range: 67-210 mm). Ethanol 96% was adopted as sclerosant agent; the amount of ethanol injected corresponded to the 20%-30% of the cystic volume. US follow-up was planned at 2/4 weeks; MR follow-up was conducted almost at 6 months after the last treatment session. Technical success was considered as cyst disappearance or reduction of the maximum diameter <50 mm; clinical success, in those symptomatic cases, was considered as symptoms resolution or marked improvement.

Results: Eleven procedures had been performed: one in three patients, three in two patients and two in one patient. Technical success was 83.3%; clinical success was 80%. Only one patient, with a preoperative cystic diameter of 210 mm and despite three treatment sessions, had an increase in the cystic size and did not report symptoms improvement.

Conclusions: In this sample, US-guided percutaneous alcohol sclerosis was a safe and effective spleen preserving option to treat primary non-parasitic splenic cysts.

Keywords: alcohol; cyst; sclerosis; spleen; ultrasound.

MeSH terms

  • Cysts* / diagnostic imaging
  • Cysts* / therapy
  • Ethanol / therapeutic use
  • Female
  • Fluoroscopy
  • Humans
  • Male
  • Retrospective Studies
  • Sclerosis / drug therapy
  • Sclerotherapy / methods
  • Splenic Diseases* / diagnostic imaging
  • Splenic Diseases* / therapy
  • Treatment Outcome

Substances

  • Ethanol